

Eric E Figueroa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1707031/publications.pdf>

Version: 2024-02-01

8
papers

122
citations

1307594

7
h-index

1720034

7
g-index

9
all docs

9
docs citations

9
times ranked

175
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992. <i>Molecular Pharmacology</i> , 2018, 94, 926-937.	2.3	39
2	LRRRC8A homohexameric channels poorly recapitulate VRAC regulation and pharmacology. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C293-C303.	4.6	19
3	CysLT1 receptor antagonists pranlukast and zafirlukast inhibit LRRRC8-mediated volume regulated anion channels independently of the receptor. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 317, C857-C866.	4.6	15
4	The LRRRC8 volume-regulated anion channel inhibitor, DCPIB, inhibits mitochondrial respiration independently of the channel. <i>Physiological Reports</i> , 2019, 7, e14303.	1.7	15
5	Pore Polarity and Charge Determine Differential Block of Kir1.1 and Kir7.1 Potassium Channels by Small-Molecule Inhibitor VU590. <i>Molecular Pharmacology</i> , 2017, 92, 338-346.	2.3	13
6	A SWELL time to develop the molecular pharmacology of the volume-regulated anion channel (VRAC). <i>Channels</i> , 2022, 16, 27-36.	2.8	10
7	Zinc pyrithione activates the volume-regulated anion channel through an antioxidant-sensitive mechanism. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C1088-C1098.	4.6	8
8	Discovery, characterization, and preclinical development of a Kir4.1 (KCNJ10) inhibitor for the treatment of hypertension. <i>FASEB Journal</i> , 2018, 32, 829.8.	0.5	0